RecruitingPhase 2NCT05378100

Ketamine for Multiple Sclerosis Fatigue

Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue (INKLING-MS)


Sponsor

Johns Hopkins University

Enrollment

110 participants

Start Date

Jan 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether low-dose ketamine — a medication already used for pain and depression — can reduce fatigue in people with multiple sclerosis (MS), a chronic condition of the nervous system. **You may be eligible if...** - You are between 18 and 65 years old with a diagnosis of multiple sclerosis - Fatigue is one of your main symptoms (measured by a standard questionnaire) - You are able to walk at least 20 feet, even with support - You have access to the internet and can use a computer, tablet, or smartphone - You are medically stable **You may NOT be eligible if...** - You have a history of psychosis or a condition that would make ketamine unsafe - You are pregnant or planning to become pregnant - You have certain liver or kidney problems - You have an active substance use disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKetamine

Infusion of ketamine 0.5 mg/kg over 40 minutes

DRUGMidazolam

Infusion of midazolam 0.05 mg/kg over 40 minutes


Locations(1)

Johns Hopkins University

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05378100


Related Trials